Of the ten postings in this thread, Genesis Therapeutics (ID: 22666537) is the most strategically revealing because of what it doesn't ask for. A drug discovery company is openly recruiting engineers with "no biology or chemistry experience required." That single line is the entire thesis of the company encoded in a job ad.

The Stack Signal (Inferred)

The posting describes "novel neural networks to predict molecular properties." In 2020, that almost certainly means graph neural networks (GNNs) — molecules are graphs, and message-passing architectures were the hot research frontier for cheminformatics. Expect a Python/PyTorch shop with heavy GPU infrastructure, RDKit for molecule manipulation, and likely some interaction with wet-lab data pipelines. The interesting choice is what they're not doing: they're not buying QSAR software or licensing Schrödinger's stack. They're betting the entire R&D engine on deep learning replacing decades-old physics-based simulations.

Stage & Direction

The team description — "graduates from Stanford, UC Berkeley, MIT. Previously worked at Facebook..." — is classic early-stage pedigree signaling. They're recruiting on prestige because they don't yet have shipping product or clinical milestones to point to. "Small team of excellent software engineers" + "South San Francisco" (biotech corridor) + "flexible WFH" tells you: Series A or early B, probably ~15-30 people, building the platform before the pipeline.

Skills & Trends

• The hybrid bet: "hybrid AI + biotech" is the explicit positioning. They want ML talent over domain talent — a wager that bringing FAANG-caliber engineering into pharma is the unlock, not hiring more chemists.
• Translatability premium: By dropping the chemistry requirement, they're tapping the much larger pool of senior ML engineers who would never consider pharma. Smart arbitrage.

Flags

Green: Honest about being a learning environment ("we all learn from each other"). Specific about the problem domain. Doesn't pretend to be a tech company that happens to do biology — owns the hybrid identity.

Yellow: No salary band, no equity range, no team size disclosed. The Stanford/MIT/FAANG name-dropping is a tell that pedigree filtering matters here, which can compress diversity of thought in a field that already suffers from groupthink. Also: onsite-required in SSF is a hard constraint right as the world is rethinking remote work.